Full Text Journal Articles from
Abstract 30830062


Find full text journal articles

Clinical features, outcomes and treatment in children with drug induced Stevens-Johnson syndrome and toxic epidermal necrolysis.

PMID: 30830062 (view PubMed database entry)
DOI: 10.23750/abm.v90i3-s.8165 (read at publisher's website )
PMCID: PMC6502171 (free full text version available)

Download PDF Download PDF

Lucia Liotti, Silvia Caimmi, Paolo Bottau, Roberto Bernardini, Fabio Cardinale, Francesca Saretta, Francesca Mori, Giuseppe Crisafulli, Fabrizio Franceschini, Carlo Caffarelli,

Stevens-Johnson syndrome (SJS) and toxic epidermal necrolysis (TEN), which can be considered a late-onset allergic reaction, can cause serious long-term sequelae. SJS/TEN are considered a spectrum of life-threatening adverse drug reactions. They have the same clinical manifestations and the only difference is in the extent of epidermal detachment. These conditions are associated with high mortality, although incidence of SJS/TEN is rare in children. SJS/TEN is an adverse drug reaction influenced by genes that involve pharmacokinetics, pharmacodynamics and immune response. Infective agents are additional influencing factors. Anticonvulsants and antibiotics, and especially sulphonamides and non-steroidal anti-inflammatory drugs, are among the drugs that were predominantly suspected of triggering SJS/TEN. No evidence-based standardized treatment guidelines for SJS or TEN are currently available. The usual treatment is mainly founded on the withdrawal of the suspected causative agent and supportive therapy. In pediatric patients, the specific therapeutic strategies are controversial and comprise systemic corticosteroids and the use of intravenous immunoglobulin (IVIG). More recently, new therapeutic approaches have been used, such as immunosuppressive therapies, including cyclosporine and TNF-α inhibitors.

Acta Biomed (Acta bio-medica : Atenei Parmensis)
[2019, 90(3-S):52-60]

Cited: 1 time

AltMetric Statistics


0.4652 s